分组1 - TriSalus Life Sciences, Inc. reported a quarterly loss of $0.27 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.22, and compared to a loss of $0.21 per share a year ago, indicating an earnings surprise of -22.73% [1] - The company posted revenues of $11.21 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.52%, and this represents an increase from year-ago revenues of $7.36 million [2] - TriSalus Life Sciences, Inc. shares have declined approximately 28.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] 分组2 - The earnings outlook for TriSalus Life Sciences, Inc. is uncertain, with current consensus EPS estimates of -$0.16 on $11.38 million in revenues for the coming quarter and -$0.86 on $44.31 million in revenues for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 42% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact the stock's performance [8]
TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates